ClinicalTrials.gg
RecruitingNCT06716151Updated Jan 20, 2025

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

A Phase 1 interventional study of HB0034 and HB0034 matching placebo in Healthy, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.

Read the detailed description

This study consisted of a single-dose escalation study and a multi-dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034 in Chinese healthy subjects.

02

Conditions studied

  • Healthy

Keywords

  • Healthy subjects
03

In context

Lead sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd. is the lead sponsor of 19 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects age ≥ 18 and ≤ 55 years.
  • (BMI) ≥ 17.5 and ≤ 32 kg/m².
  • Normal , blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not .

Signed and dated written prior to admission to the study in accordance with GCP and local legislation.

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.

Current or history of . • Family history of premature Coronary Heart Disease (CHD)

  • History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
  • Pregnant or Breasting feeding subject. Women with a positive pregnancy test.
  • Further exclusion criterias apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Comparator: HB0034 dose group 1

    6 subjects receive a single-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 2

    6 subjects receive a single-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 3

    6 subjects receive a single-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 4

    6 subjects receive a single-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 5

    6 subjects receive a single-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 6

    8 subjects receive a multi-dose of HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Experimental
    Active Comparator: HB0034 dose group 7

    8 subjects receive a multi-dose of HB0034 a recombinant humanized anti-IL-36R IgG1 monoclonal antibody

    Drug: HB0034

  • Placebo comparator
    Placebo group

    17 subjects receive placebo

    Drug: HB0034 matching placebo

Interventions

  • DrugHB0034

    Recombinant Humanized Anti-IL-36R Monoclonal antibody

  • DrugHB0034 matching placebo

    HB0034 matching Palcebo

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with drug related adverse events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational drug

    Time frame: up to 113 days

Secondary outcomes

  1. Cmax

    The maximum measured concentration of the analysis in plasma

    Time frame: Up to 113 days

  2. AUC0-infinity

    The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity

    Time frame: up to 113 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Nov 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Dec 6, 2024
Primary completionEst.
Nov 20, 2025
CompletionEst.
Nov 20, 2025
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716151
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 6, 2024
Primary completion
Nov 20, 2025 (estimated)
Completion
Nov 20, 2025 (estimated)
Last update
Jan 20, 2025

Study contacts

Yuan Tang
Contact
yuan.tang@huaota.com
+86 15821321563
Qiaoxia Qian
Contact
qiaoxia.qian@huaota.com
+86 18555690860

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0034

Start the discussion